DALLAS, April 15, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Antigenics Inc. (Nasdaq:AGEN). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/AGEN
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Antigenics Inc. (AGEN) is a biotechnology company developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Oncophage has been tested in phase III clinical trials for the treatment of renal cell carcinoma, a common type of kidney cancer, and for the treatment of metastatic melanoma. It has also been tested in phase I and phase II clinical trials in a range of indications and is in phase II clinical trials in glioma, a type of brain cancer.
Message Board Search for AGEN: http://www.boardcentral.com/boards/AGEN
In the report, the analyst notes:
"AGEN recently reported its results for the quarter and year ended December 31, 2009. The Company reported net income attributable to common stockholders of $1.7 million, or $0.02 per share, basic and diluted, for the fourth quarter of 2009, compared with net income attributable to common stockholders in the fourth quarter of 2008 of $3.9 million, or $0.06 per share, basic and diluted.
"The Company's net cash burn (cash used in operating activities plus capital expenditures and dividend payments) for the years ended December 31, 2009, and 2008, was $25.2 million and $29.9 million, respectively. The 2009 net cash burn primarily reflects the Company's efforts to support Oncophage® (vitespen), the Company's novel patient-specific cancer vaccine, in Russia, Europe and other territories, while also executing cost containment efforts."
To read the entire report visit: http://www.beaconequity.com/i/AGEN
See what investors are saying about AGEN at penny stock forum
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.